7 days ago
TARS
AnalystsEddie HickmanEddie Hickman's Stock Forecasts
AnalystsEddie Hickman
Sectors:
Industries:
Analyst Ranking
Top 19%
#963 out of 5208 analysts
Average Return
+37.57%
Win Rate
79%15 out of 19
Risk vs Reward
Poor
Good
Eddie Hickman's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Promis Neurosciences IncPMN | +173.33% | $9.00 | $24.60 | 2025-11-18 - 2026-03-03 | Strong Buy |
Iveric Bio IncISEE | +167.40% | $14.94 | $39.95 | 2022-09-07 - 2023-07-10 | Strong Buy |
Promis Neurosciences IncPMN | +93.24% | $12.73 | $24.60 | 2026-02-06 - 2026-03-03 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +85.16% | $16.98 | $31.44 | 2023-09-11 - 2024-09-10 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +70.70% | $42.56 | $72.65 | 2025-02-26 - 2026-02-25 | Strong Buy |
Eddie Hickman Analyst Color
Get additional color on Eddie Hickman's coverage of popular stocks
3 months ago
HELP
a year ago
ZVRA
Eddie Hickman's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Tarsus Pharmaceuticals IncTARS | 7 | Strong Buy | $90.00 | +17.57% | Maintains | 7 days ago |
Promis Neurosciences IncPMN | 3 | Strong Buy | $35.00 | +42.28% | Maintains | a month ago |
Atai Beckley NvATAI | 1 | Strong Buy | $11.00 | +198.10% | Initiates Coverage On | a month ago |
Cybin IncHELP | 2 | Strong Buy | $48.00 | +507.59% | Maintains | 3 months ago |
Zevra Therapeutics IncZVRA | 1 | Strong Buy | $22.00 | +146.91% | Maintains | a year ago |
Gh Research PLCGHRS | 1 | Strong Buy | $32.00 | +109.15% | Initiates Coverage On | a year ago |
Outlook Therapeutics IncOTLK | 3 | Strong Buy | $12.00 | N/A | Reiterates | a year ago |
Iveric Bio IncISEE | 1 | Strong Buy | $35.00 | N/A | Maintains | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.